Physical QoL Mental QoL CES-D
  β SE β SE β SE
Constant 63.38** 8.71 41.18** 10.78 2.81 1.78
Age 0.06 0.12 0.19 0.14 -0.04† 0.02
Gender            
Female vs. Male 2.86 2.69 5.07† 2.74 -0.47 0.47
Time on ART            
=< 6 months vs. > 6 months -7.88** 2.28 0.19 2.29 0.27 0.39
ART Combination            
AZT + NVP + 3TC vs. AZT + EFV + 3TC -1.68 2.26 -4.89† 2.62 0.87† 0.46
AZT + NVP + 3TC vs. All others 0.55 2.12 0.89 2.52 -0.35 0.43
CD4 Rank            
< 200 vs. 200 – 350 -1.02 2.16 -3.26 2.40 0.12 0.41
< 200 vs. 351 – 500 -2.57 2.66 -2.36 2.99 0.28 0.53
< 200 vs. > 500 0.07 3.41 -4.54 3.86 0.01 0.68
ART Knowledge -1.22 2.73 4.19 3.21 0.05 0.57
Social Support 0.13* 0.05 0.12* 0.06 -0.02* 0.01
HIV Stigma -0.21 0.15 -0.18 0.18 0.03 0.03
Side-Effect Severity -6.85** 1.23 -6.35** 1.40 1.12** 0.24
**P< 0.01; *p< 0.05; †p< 0.1; β = Estimated Coefficient Correlation; SE = Standard Error; Physical QoL = Physical Quality of Life; Mental QoL = Mental Quality of Life; CES-D = Transformed Center for Epidemiologic Studies Depression Scale;Zidovudine (AZT); Nevirapine (NVP); lamivudine (3TC); Efavirenz (EFV). All the models were further adjusted for covariates listed in table 2.
Table 3: Predictors of Quality of Life and CESD among 120 HIV-Positive Individuals in China.